Though the stock hit its record high a month ago, Sun Pharma remains the safest bet in the pharma sector. A strong balance sheet, robust cash flows and consistent performance make the company highly investment-worthy. It commands leadership in six therapeutic areas and boasts of one of the highest operating margins in the industry. Its prospects in the US market have improved after the Taro takeover.
Pharma Sector has done well inspite of the carnage recently witnessed. The company gave good returns to the investors as per the given data below
Buy on declines around Rs.425 levels and hold for a 2-3 years period for a good returns. The scrip gives capital protection and good gains in next bull run
Bought to you by